Search results for "TC"

showing 10 items of 9993 documents

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

Secukinumab efficacy in the treatment of nail psoriasis: a case series

2018

Nail involvement is frequent in patients with psoriasis, especially those with psoriatic arthritis (PsA), and can significantly impair quality of life (QoL). It is typically difficult to treat compared with skin lesions, although several conventional treatment options are available. The aim of this article is to describe our experience in the treatment of nail psoriasis with secukinumab in a case series. Fifteen patients (11 males and 4 females), with moderate-severe plaque psoriasis and nail psoriasis, eligible for systemic therapy, and received secukinumab. The Psoriasis Area and Severity Index (PASI) and body surface area (BSA) assessed cutaneous severity. Nail Psoriasis Severity Index (…

0301 basic medicineAdultMalemedicine.medical_specialtyDermatologyNail psoriasisAntibodies Monoclonal HumanizedSeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisNail Diseases0302 clinical medicineQuality of lifePsoriasisSeverity of illnessMedicineHumansPsoriasisIn patientPsoriasibusiness.industrysecukinumabfungifood and beveragesAntibodies MonoclonalMiddle Agedmedicine.diseaseNail DiseaseDermatologyhumanities030104 developmental biologyNAPSITreatment OutcomeNail diseasenail psoriasiQuality of LifeSecukinumabFemalebusinessHuman2708
researchProduct

Antiepileptic drug reduction and increased risk of stimulation-evoked focal to bilateral tonic-clonic seizure during cortical stimulation in patients…

2017

Introduction: Stimulation-evoked focal to bilateral tonic-clonic seizure (FBTCS) can be a stressful and possibly harmful adverse event for patients during cortical stimulation (CS). We evaluated if drug load reduction of anti epileptic drugs (AEDs) during CS increases the risk of stimulation-evoked FBTCS. Material and methods: In this retrospective cohort study, we searched our local database for patients with drug resistant epilepsy who underwent invasive video-EEG monitoring and CS in the University Hospital la Fe Valencia from January 2006 to November 2016. The AED drug load was calculated with the defined daily dose. We applied a uni- and multivariate logistic regression model to estima…

0301 basic medicineAdultMalemedicine.medical_specialtyDrug Resistant EpilepsyNeurologyAdolescentDrug-Related Side Effects and Adverse ReactionsStimulation03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineEpilepsy surgerySeizuresmedicineOdds RatioHumansEpilepsy surgeryAdverse effectRetrospective Studiesbusiness.industryRetrospective cohort studyElectroencephalographyOdds ratioMiddle Agedmedicine.diseaseElectric Stimulation030104 developmental biologyDefined daily doseLogistic ModelsTreatment OutcomeNeurologyElectrical stimulationWithdrawalAnesthesiaDefined daily doseAnticonvulsantsEpilepsy GeneralizedFemaleNeurology (clinical)Epilepsies PartialEpilepsy Tonic-ClonicSafetybusinessGeneralized tonic-clonic seizure030217 neurology & neurosurgeryEpilepsybehavior : EB
researchProduct

Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII).

2016

Hereditary angioedema with normal C1 esterase inhibitor and mutations in the F12 gene (HAE-FXII) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. It occurs nearly exclusively in women. We report our experience treating HAE-FXII with discontinuation of potential trigger factors and drug therapies. The study included 72 patients with HAE-FXII. Potential triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors. Drug treatment comprised plasma-derived C1 inhibitor (pdC1-INH) for acute swelling attacks and progestins, tranexamic acid, and danaz…

0301 basic medicineAdultMalemedicine.medical_specialtyExacerbationAdolescentImmunologyAngiotensin-Converting Enzyme InhibitorsGastroenterologyChemopreventionC1-inhibitorHereditary Angioedema Type III03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicinemedicineImmunology and AllergyHumansHereditary Angioedema Type IIIChildAgedDanazolbiologybusiness.industryEstrogensMiddle Agedmedicine.diseaseSurgeryDiscontinuation030104 developmental biologyTreatment Outcome030228 respiratory systemQuinaprilHereditary angioedemaFactor XIIMutationbiology.proteinDisease ProgressionFemalebusinessComplement C1 Inhibitor ProteinTranexamic acidBiomarkersmedicine.drugAllergy
researchProduct

A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Di…

2019

Background and aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naive and non-naive patients. Results A total of 632 patients [735 total treatments] were included. Among naive patients, a cli…

0301 basic medicineAdultMalemedicine.medical_specialtyInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseGastrointestinal AgentsInternal medicinemedicineAdalimumabHumansYoung adultSicilypropensity scoreCrohn's diseasebusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabGeneral MedicineOdds ratiomedicine.diseaseAdalimumab; infliximab; propensity score; Adalimumab; Adult; Crohn Disease; Female; Gastrointestinal Agents; Humans; Infliximab; Male; Propensity Score; Sicily; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultInfliximab030104 developmental biologyTreatment OutcomeCohortPropensity score matching030211 gastroenterology & hepatologyFemalebusinessinfliximabmedicine.drug
researchProduct

High-frequency blood flow-restricted resistance exercise results in acute and prolonged cellular stress more pronounced in type I than in type II fib…

2021

Myocellular stress with high-frequency blood flow-restricted resistance exercise (BFRRE) was investigated by measures of heat shock protein (HSP) responses, glycogen content, and inflammatory markers. Thirteen participants [age: 24 ± 2 yr (means ± SD), 9 males] completed two 5-day blocks of seven BFRRE sessions, separated by 10 days. Four sets of unilateral knee extensions to failure at 20% of one-repetition maximum (1RM) were performed. Muscle samples obtained before, 1 h after the first session in the first and second block (

0301 basic medicineAdultMalemedicine.medical_specialtyPhysiologyInflammationStress (mechanics)03 medical and health sciencesYoung Adult0302 clinical medicinePhysiology (medical)Internal medicinemedicineStress ProteinsHumansType i muscle fibersMuscle SkeletalExerciseKaatsuFiber typeChemistryResistance trainingResistance Training030229 sport sciencesBlood flowMicroRNAs030104 developmental biologyEndocrinologyMuscle Fibers Slow-TwitchRegional Blood FlowFemalemedicine.symptomJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism.

2017

Abstract Context Supplemental selenium (Se) may affect the clinical course of Graves disease (GD). Objective Evaluate efficacy of add-on Se on medical treatment in GD. Design Double-blind, placebo-controlled, randomized supplementation trial. Setting Academic endocrine outpatient clinic. Patients Seventy untreated hyperthyroid patients with GD. Intervention Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo. MMI was discontinued at 24 weeks in euthyroid patients. Main Outcome Measures Response rate (week 24), recurrence rate (week 36), and safety. Results A response was registered in 25 of 31 patients (80%) and in 27 of 33 (82%) a…

0301 basic medicineAdultMalemedicine.medical_specialtySide effectEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)PlaceboBiochemistryHyperthyroidismlaw.inventionPlacebos03 medical and health sciencesSelenium0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawRecurrenceInternal medicineMedicineOutpatient clinicHumansEuthyroidAdverse effectbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseGraves Disease030104 developmental biologyEndocrinologyTreatment OutcomeDietary SupplementsFemalebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

Does the educational level of women influence hand grip and pinch strength in carpal tunnel syndrome?

2020

Abstract Background Grip and pinch strength are relevant functional variables for various activities of daily life and are related to the quality of life of patients with carpal tunnel syndrome (CTS). Objective The main aim was to analyze the relationship between grip and pinch strength and the educational level in women with CTS. Study design Cross-sectional study. Methods Thirty-one female patients with CTS awaiting surgery were assigned to the low education group if they only had primary education level (completed or not) and the high education group for those having higher education level. The assessments included: grip strength, pinch strength, Visual Analogue Scale, Quick DASH Questio…

0301 basic medicineAdultMalemedicine.medical_specialtyVisual analogue scalePinch Strength03 medical and health sciencesGrip strength0302 clinical medicineHand strengthSurveys and QuestionnairesMedicineHumansPinch StrengthQuick dashCarpal tunnel syndromeLife StyleAgedPain MeasurementHand Strengthbusiness.industryCatastrophizationSignificant differenceGeneral MedicineMiddle Agedmedicine.diseaseCarpal Tunnel Syndromebody regions030104 developmental biologyCross-Sectional StudiesTreatment OutcomePhysical therapyQuality of LifeEducational StatusPain catastrophizingFemalebusiness030217 neurology & neurosurgeryMedical hypotheses
researchProduct

Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic res…

2015

Abstract Objective This was a retrospective data analysis to evaluate the treatment response to enzyme replacement therapy (ERT) with Velaglucerase alfa using whole-body magnetic resonance imaging (MRI). Materials and methods A baseline and follow-up MRI were performed on 18 Gaucher Type 1 patients at an interval of 11.6 months. The MRI score systems determined the Bone-Marrow-Burden (BMB) score, the Dusseldorf-Gaucher score (DGS), and the Vertebra-Disc-Ratio (VDR). The Severity Score Index Type 1 (GD-DS3) was also assessed. Results The baseline MRI medians were: BMB, 7.00; DGS, 3.00; and VDR: 1.70; while, the follow-up MRI medians were: BMB, 7.00; DGS, 3.00; and VDR: 1.73. The baseline GD-…

0301 basic medicineAdultMalemedicine.medical_specialtyWhole body imagingSeverity of Illness Index03 medical and health sciences0302 clinical medicineBone MarrowStatistical significanceSeverity of illnessmedicineHumansEnzyme Replacement TherapyWhole Body ImagingStage (cooking)Molecular BiologyAgedRetrospective StudiesGaucher Diseasemedicine.diagnostic_testbusiness.industryVelaglucerase alfaPlatelet CountMagnetic resonance imagingRetrospective cohort studyCell BiologyHematologyEnzyme replacement therapyMiddle AgedMagnetic Resonance ImagingRecombinant ProteinsSurgery030104 developmental biologyTreatment OutcomeMolecular MedicineGlucosylceramidaseFemaleRadiologybusiness030215 immunologymedicine.drugFollow-Up StudiesBlood cells, moleculesdiseases
researchProduct

Molecular and clinical studies in five index cases with novel mutations in the GLA gene

2016

Fabry disease is a metabolic and lysosomal storage disorder caused by the functional defect of the α-galactosidase A enzyme; this defect is due to mutations in the GLA gene, that is composed of seven exons and is located on the long arm of the X-chromosome (Xq21–22). The enzymatic deficit is responsible for the accumulation of glycosphingolipids in lysosomes of different cellular types, mainly in those ones of vascular endothelium. It consequently causes a cellular and microvascular dysfunction. In this paper, we described five novel mutations in the GLA gene, related to absent enzymatic activity and typical manifestations of Fabry disease. We identified three mutations (c.846_847delTC, p.E…

0301 basic medicineAdultMalep.R227Pnovel moutationAdolescentc.639 + 5G > TMutation MissenseBiologyLeft ventricular hypertrophy03 medical and health sciencesExonYoung Adult0302 clinical medicineSettore BIO/13 - Biologia ApplicataGeneticsmedicinefabry; novel moutationMissense mutationAlpha-galactosidase AHumansPoint MutationCornea verticillataGenetic Predisposition to DiseaseChildfabryGLA genec.846_847delTCGeneticsAlpha-galactosidasePoint mutationFabry disease; Alpha-galactosidase A; c.846_847delTC; p.E341X; p.C382X; p.R227P; c.639 + 5G > Tp.E341XGeneral MedicineMiddle Agedmedicine.diseaseMolecular biologyFabry diseaseStop codon030104 developmental biologyp.C382Xalpha-Galactosidasebiology.proteinFabry DiseaseFemalemedicine.symptom030217 neurology & neurosurgery
researchProduct